Becton, Dickinson (BDX) said it has applied for a CE Mark in the European Union for its Liverty TIPS Stent Graft, a next-generation device designed to treat complications from portal hypertension in the liver.
The company said the device targets patients with cirrhosis, a condition affecting an estimated 58 million people globally, and aims to improve outcomes by reducing elevated blood pressure in the liver through TIPS procedures.
The Liverty stent features an adjustable diameter, flexible self-expanding frame, and advanced coating designed for precision placement and durability, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments